Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;7(3):173-179.
doi: 10.1159/000513771. Epub 2021 Feb 18.

Bibliometric Analysis of the 50 Most Cited Publications in Hidradenitis Suppurativa

Justine R Seivright  1 , Alyssa M Thompson  2 , Natalie M Villa  3 , Vivian Y Shi  4 , Jennifer L Hsiao  3
Affiliations

Bibliometric Analysis of the 50 Most Cited Publications in Hidradenitis Suppurativa

Justine R Seivright et al. Skin Appendage Disord. 2021 Apr.

Abstract

Background: Hidradenitis suppurativa (HS) has historically been a neglected disease. However, research in this field has grown exponentially in the past decade.

Methods: The top-cited HS articles from 1950 to 2020 were analyzed for authorship, study topic, study design, and senior author country of origin.

Results: We found that nearly half of the top 50 cited articles were published in the last decade, with a recent increase in the number of highly cited randomized controlled trials. Medical treatment is the most cited topic, with more attention on biologics over time. The past decade has seen an increase in highly cited articles on HS comorbidities, pathogenesis, and clinical practice guidelines. There has been a predominance of highly cited HS research from Europe; highly cited studies from Africa, Asia, Australia, and South America are lacking.

Conclusions: Recent advances in HS research have focused on investigating HS pathogenesis and drug development, highlighting disease comorbidities, and improving evidence-based care. Studies in pathogenesis have translated into a paradigm shift in medical treatment from antibiotics to incorporation of targeted therapies in recent years. Encouraging growth of HS research in countries outside of North America and Europe may help to optimize HS care globally.

Keywords: Bibliometric; Citation; Hidradenitis suppurativa; Impact factor; Publication.

PubMed Disclaimer

Conflict of interest statement

V.Y.S. is a stock shareholder of Learn Health and has served as an advisor, investigator, and/or speaker for Sanofi Genzyme, Regeneron, AbbVie, Burt's Bees, Dermira, Eli Lilly, Novartis, Pfizer, Galderma, Leo Pharma, SUN Pharma, Menlo Therapeutics, GpSkin, and Skin Actives Scientific. J.L.H. has served as an advisor for Novartis. There was no financial transaction for the preparation of this manuscript. J.S., A.T., and N.V. report no conflicts of interest.

Figures

Fig. 1
Fig. 1
Study topics in the 50 top-cited hidradenitis suppurativa articles.
Fig. 2
Fig. 2
Number of articles and their study design by the decade of publication.
Fig. 3
Fig. 3
Senior-author countries of origin.
See this image and copyright information in PMC

References

    1. Savage KT, Gonzalez Brant E, Flood KS, Salian P, Porter ML, Kimball AB. Publication trends in hidradenitis suppurativa from 2008 to 2018. J Eur Acad Dermatology Venereol. 2020 Sep;34((9)):1885–9. - PubMed
    1. Naik HB, Lowes MA. A call to accelerate hidradenitis suppurativa research and improve care-moving beyond burden. JAMA Dermatol. 2019;155((9)):1005–6. - PMC - PubMed
    1. Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59((4)):596–601. - PubMed
    1. Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol. 2017;153((8)):760–4. - PMC - PubMed